Will Merck See A $100 Million Fine, In The UK — Just As Pfizer Saw?

While Kenilworth can certainly absorb such an amount, it is not optimal for its global reputation to be labeled “anti-competitive” — by a UK regulator. [Just one of many backgrounders here — this one from October of 2015.] Pfizer paid about $100 million, in fines for its pricing tactics, related to Epanutin — an epilepsy drug, in the UK at Christmas 2016.

The finding regarding Merck is still preliminary, and through settlement negotiations (and appeals), may be reversed. Even so, Merck has seen bio-similar incursion, in this market as the graphic indicates, from its peak UK sales years of 2014-15. From The Independent (UK), then:

. . . .According to the Competition and Markets Authority’s provisional findings released on Tuesday, one of the US company’s European units – Merck Sharp & Dohme – abused its dominant market position through a discount scheme for the drug Remicade – generically known as infliximab – which is used to treat rheumatoid arthritis and Crohn’s disease.

“The CMA has provisionally found that MSD broke competition law by abusing its dominant position through a discount scheme for Remicade that was likely to restrict competition from ‘biosimilar’ versions of infliximab that were new to the market,” the competition watchdog said in a statement.. . .

Now you know — as the whole  fam-damily evaporates, once more. . . . smile.


There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: